Atara Biotherapeutics (ATRA) Enterprise Value (2022 - 2025)
Atara Biotherapeutics' Enterprise Value history spans 4 years, with the latest figure at -$8.5 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 80.04% year-over-year to -$8.5 million; the TTM value through Dec 2025 reached -$8.5 million, up 80.04%, while the annual FY2025 figure was -$8.5 million, 80.04% up from the prior year.
- Enterprise Value reached -$8.5 million in Q4 2025 per ATRA's latest filing, down from -$5.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.7 million in Q3 2025 to a low of -$205.4 million in Q1 2023.
- Average Enterprise Value over 4 years is -$66.1 million, with a median of -$49.2 million recorded in 2023.
- Peak YoY movement for Enterprise Value: tumbled 113.29% in 2023, then skyrocketed 87.68% in 2025.
- A 4-year view of Enterprise Value shows it stood at -$93.1 million in 2022, then soared by 44.43% to -$51.7 million in 2023, then rose by 17.84% to -$42.5 million in 2024, then soared by 80.04% to -$8.5 million in 2025.
- Per Business Quant, the three most recent readings for ATRA's Enterprise Value are -$8.5 million (Q4 2025), -$5.7 million (Q3 2025), and -$16.9 million (Q2 2025).